不是传染性单核细胞增多症:在急诊识别 HIV
本文通过同一患者三次急诊就诊,展示未治疗 HIV 感染的急性感染期、慢性潜伏期和晚期三个阶段。急性期需重视接触史并对高怀疑者加做 HIV RNA,不能因 Ag/Ab 筛查或快速检测阴性而排除。慢性潜伏期通常无症状,应落实至少一次、不依赖风险因素的常规 HIV 筛查,并采用不参加即不做的 opt-out 方式。晚期若出现明显低氧血症但胸片表现相对轻微,应高度警惕肺孢子菌肺炎并安排住院。目标是尽早在第一或第二次就诊时诊断,避免进展到晚期疾病。
要点
- 高危接触史后 2~4 周出现发热、咽炎、淋巴结肿大、斑丘疹或黏膜皮肤溃疡,即使 Ag/Ab 筛查阴性,仍应怀疑急性 HIV 并送 HIV RNA。
- 急性 HIV 是高病毒血症状态,病毒载量可达数百万 copies/mL,传播风险高;尽早诊断可尽快抑制病毒并保护免疫功能。
- 慢性潜伏期常多年无症状,不要根据主观风险判断是否检测;美国指南建议青少年和成人至少进行一次 HIV 筛查。
- 急诊若遇已确认或疑似晚期 HIV 患者出现进行性劳力性呼吸困难、干咳、发热、低氧,而胸片仅有轻微双侧肺门间质改变,应高度警惕 PJP。
- AIDS 定义性机会感染本身就提示晚期疾病,无论 CD4 计数如何;此类患者应确认 HIV、扩大机会感染排查并早期请感染科或收入院。
适用人群与场景
- 急诊科中近期有新性伴侣或注射吸毒史并出现发热、咽痛、皮疹等病毒样表现的年轻成人,需考虑急性 HIV。
- 既往未做过 HIV 检测、因其他原因就诊的无症状青少年和成人,属于常规 HIV 筛查机会人群。
- 数周进行性劳力性呼吸困难、干咳、发热并伴低氧血症的患者,若存在晚期 HIV 风险,应警惕 PJP 并收入院。
诊断标准与关键阈值
- 急性逆转录病毒综合征约在感染后 2~4 周出现;发热、咽炎、淋巴结肿大、斑丘疹和黏膜皮肤溃疡是最具区分度的表现。
- HIV 标志物可检出时间:约第 10 天 HIV RNA 可检出;约 2 周 p24 抗原可检出;约 3 周 HIV 抗体开始出现。
- AIDS 定义性机会感染一旦出现,即确立晚期疾病,不论 CD4 计数高低。
- 低氧血症明显而胸片异常相对轻微,是警觉 PJP 的关键临床线索。
处置流程与药物剂量
- 第一步:对急性病毒样表现者,先想到急性 HIV,并通过非评判性的性接触史和注射吸毒史判断暴露风险。
- 第二步:若高度怀疑急性 HIV,即使 Ag/Ab 筛查阴性,也应在同次就诊送 HIV RNA,并确保有结果随访路径或安排复测。
- 第三步:对符合条件且既往未检测者,在急诊按当地政策采用 opt-out 方式提供 HIV 筛查,告知除非拒绝否则将检测。
- 第四步:若筛查反应性,进入 HIV-1/HIV-2 鉴别检测;若鉴别结果为阴性或不确定,则用 HIV RNA 进一步明确。
- 第五步:对疑诊 PJP 的晚期患者,立即确认 HIV 状态,早期联系收治团队或感染科,扩大机会感染排查并安排住院。
- 床旁检测注意:强疑急性 HIV 时,快速检测不能排除感染;许多快速检测仅测抗体,应送实验室 Ag/Ab 并考虑 HIV RNA。
红旗征与不能漏的情况
- 近期高危暴露后出现病毒样综合征但 Monospot 或床旁快速 HIV 检测阴性,不可据此排除急性 HIV。
- 晚期 HIV 风险患者出现明显低氧血症、活动后氧饱和度进一步下降,但胸片仅有轻微双侧肺门间质改变,应立即考虑 PJP。
- 出现 AIDS 定义性机会感染即提示晚期 HIV,需要立即住院并评估是否合并其他机会感染。
研究设计与关键结果
- 原文未提及
证据类型、等级与局限
- 本文为教学文章,未给出系统检索方法或证据分级。
- 文中 HIV 标志物检出时序概念来源于 Fiebig EW et al. 2003;CD4 与 HIV RNA 自然史示意曲线概念来源于 Fauci AS et al 1996。
- 筛查流程参考 CDC/APHL 2018 年血清或血浆标本实验室 HIV 检测算法快速参考指南。
- 原文未提及其余关键结论的具体证据等级或推荐强度。
对床旁实践的改变
- 不能仅凭 Monospot 阴性、床旁快速 HIV 检测阴性或实验室 Ag/Ab 筛查阴性排除高怀疑的急性 HIV,应加送 HIV RNA。
- 把 HIV 筛查作为常规医疗内容而非按主观风险选择性筛查,使用 opt-out 方式可提高接受度并减少歧视。
- 对可疑晚期 HIV 合并低氧血症患者,应以氧合和生理状态而非胸片严重程度决定是否收住院。
- 每一次急诊就诊都应被视为 HIV 筛查机会,目标是在急性期或无症状慢性期诊断,避免患者进展到机会性感染。
指南或共识出处
- CDC/APHL recommended laboratory HIV testing algorithm for serum or plasma specimens, 2018 quick reference guide
- Fiebig EW et al. 2003
- Fauci AS et al. 1996
全文中译5 节 · 点击展开
一次急诊就诊,一次HIV识别
等到HIV被诊断出来时,患者可能已经不止一次经过急诊科。从感染HIV到确诊的中位间隔时间约为三年,美国约有八分之一的HIV感染者尚不知道自己已感染。那些年往往充满了因其他原因而进行的医疗就诊。
本文跟随一位患者经历三次急诊就诊,每一次代表未治疗HIV感染的不同时间点:急性感染期、慢性感染期和晚期疾病。
每个阶段都会改变我们应当识别的表现、应当进行的检测以及应当如何解读结果。
下图显示了这一轨迹:在急性感染期、慢性感染期和晚期疾病过程中,CD4计数下降,HIV RNA发生变化。随后的三次急诊就诊呈现的是沿同一病程的不同快照。
未治疗HIV的自然史。在急性期、慢性期和AIDS期,随着HIV RNA(青色,右轴)升高,CD4+计数(紫色,左轴)下降。注意轴断裂:急性期以周为单位,其余以年为单位。曲线为示意图,未按比例绘制。概念改编自Fauci AS等,1996年。
快照1——急性HIV感染
一位年轻成人在有了新的性伴侣三周后,因发热、咽痛和皮疹就诊。嗜异性抗体试验(Monospot)为阴性,该表现被标记为另一种病毒性疾病。大多数情况下,这一诊断会是正确的。但有时,这是急性HIV感染——病毒血症和传染性处于最高水平的时期。
你应当怎么做?
想到它,然后确定暴露史是否支持这一判断。急性逆转录病毒综合征大约出现在感染后2至4周;发热、咽炎、淋巴结肿大、斑丘疹和皮肤黏膜溃疡是最具鉴别意义的特征。但该综合征缺乏特异性,因此使急性HIV在鉴别诊断中上升的,是非评判性的性和注射吸毒史。暴露史往往是区分“另一种病毒性疾病”和“今天就检测急性HIV”的关键。
了解常规筛查何时可能漏诊急性HIV。HIV抗原/抗体免疫测定同时检测p24抗原和HIV抗体,感染后诊断标志物按可预测的顺序变得可检出:
约第10天:HIV RNA变得可检出。常规抗原/抗体筛查试验不检测该指标。
约2周:p24抗原变得可检出,可能触发检测中的抗原组分。
约3周:HIV抗体开始出现。
感染后HIV标志物可检出时间。这些为人群的中位数,存在相当大的个体差异。曲线为定性示意,未按比例绘制。改编自Fiebig EW等,2003年。
不要让阴性筛查结果终结高度可疑的临床表现。如果暴露史具有说服力且急性HIV仍在鉴别诊断中,抗原/抗体检测无反应性可能只是检测过早。在同一次就诊时送检HIV RNA(核酸扩增检测),并确保有明确的结果随访路径,或在适当时安排复查。
为什么重要。急性HIV感染是一种高病毒血症状态,病毒载量可达数百万拷贝/mL,向前传播的可能性很高。早期诊断可以及时启动治疗、快速抑制病毒并保护免疫功能。
POC要点:当高度怀疑急性HIV感染时,床旁HIV检测结果阴性不应让你感到安心。许多快速检测仅检测抗体,即使是第四代快速检测在极早期感染阶段的可靠性也较低。应送检实验室抗原/抗体联合检测,并考虑检测HIV RNA,而不是仅依赖床旁检测。
快照2——慢性HIV感染/临床潜伏期
同一位患者,两年后,一般状况良好,因踝关节扭伤就诊。临床潜伏期通常无症状,常持续数年,除非有人进行检测,否则不会被发现。
这就是首次就诊漏诊的机会成本。临床潜伏期内每一次急诊接触都是另一次筛查机会。
常规筛查不应依赖于主观认定的风险。美国指南建议青少年和成人至少接受一次HIV筛查,与已知危险因素无关。因此,急诊就诊是为既往未检测过的符合条件患者提供筛查的机会。
在当地政策支持的情况下采用选择退出(opt-out)方式。将HIV筛查作为常规医疗的一部分来介绍,并告知患者除非拒绝,否则将进行检测。将检测常态化可以提高接受率,并减少因选择性识别“高风险”患者而产生的污名化。
筛查反应阳性只是诊断流程的开始,并不是最终诊断。
下一步取决于HIV-1/HIV-2鉴别试验,若鉴别结果为阴性或不确定,则需通过HIV RNA检测来明确。
HIV筛查结果解读。改编自CDC/APHL推荐的血清或血浆标本实验室HIV检测流程(2018年快速参考指南)。
HIV-2在流行病学相关人群之外并不常见,但正因如此,确证试验需要区分HIV-1和HIV-2。
快照3——晚期HIV感染
同一位患者,此次就诊表现为数周以来进行性加重的劳力性呼吸困难、干咳和发热。脉搏血氧测定显示低氧血症,且活动后血氧饱和度进一步下降。胸片显示双侧肺门周围细微的间质性阴影,相对于生理功能紊乱的程度而言,影像学表现相对不明显。
对于有晚期HIV风险的患者,这种不匹配应立即引起对耶氏肺孢子菌肺炎(PJP)的警惕。
AIDS定义性机会性感染一旦出现,无论CD4计数如何,都确立为晚期疾病。在已确诊HIV的患者中,你面前的机会性感染本身就是疾病分期的标志性事件。
不匹配是线索。在适当的临床背景下,显著的低氧血症伴有相对轻微的胸片异常应引起对PJP的警惕。应依据生理状况而非胸片表观严重程度来决定收治安排。
PJP可能不是唯一的问题。病情进展到这种程度的患者需要进行更广泛的机会性感染排查。如尚未确诊HIV,应予以确诊,并尽早请收治团队或感染科团队参与。这种表现需要收治入院。
贯穿主线:这是所有人都记得的那次就诊,也是前两个快照试图预防的那次就诊。此前每一次急诊接触都是在本病发展为晚期之前诊断HIV的机会。
结论
HIV 的三个阶段在同一个人身上可以在急诊科表现为三种截然不同的情况:急性逆转录病毒综合征、临床沉默的慢性感染和晚期疾病。诊断越早,保留免疫功能、抑制病毒血症和防止继续传播的机会就越大。
常规 opt-out 抗原/抗体筛查可识别其他情况下处于沉默状态的慢性感染。当怀疑急性感染时,对 HIV RNA 检测保持较低的送检门槛,有助于在常规筛查可靠转为阳性之前缩小诊断窗口期。
目标很简单。在第 1 或第 2 个快照时做出诊断,这样第 3 个快照就永远不会发生。
本文配合 Dakota Price 医学博士主讲的 HIV 初级保健课程。有关筛查、诊断和分期的更全面方法,请参阅“筛查与诊断”章节,包括“理解检测结果”和“回顾 HIV 分期”两课。
原文篇幅较长或含参考文献等附属内容,只翻译了正文部分,其余请阅读原文。
原文图文
The Mono That Wasn’t
Dakota Price
Oct 23, 2026
Home LITFL Clinical Cases
Recognising HIV one ED visit at a time
By the time HIV is diagnosed, the patient may already have passed through the emergency department more than once. The median interval between acquiring HIV and diagnosis is around three years, and roughly 1 in 8 people with HIV in the US do not yet know they have it. Those years are often filled with healthcare encounters for something else.
This article follows one patient across three ED visits, each representing a different point in untreated HIV infection: acute infection, chronic HIV and advanced disease.
Each stage changes what we should recognise, what we should test and how we should interpret the result.
The figure below shows the trajectory: CD4 count falls and HIV RNA changes across acute infection, chronic infection and advanced disease. The three ED presentations that follow are snapshots along that same course.
Natural history of untreated HIV. The CD4+ count (purple, left axis) falls as HIV RNA (teal, right axis) rises across the acute, chronic, and AIDS stages. Note the axis break: the acute phase is measured in weeks, the rest in years. Curves are schematic and not drawn to scale. Concept adapted from Fauci AS et al 1996
Snapshot 1 — Acute HIV
A young adult presents three weeks after a new sexual partner with fever, sore throat and rash. The Monospot is negative and the presentation is labelled another viral illness. Most of the time, that diagnosis will be correct. Sometimes, however, this is acute HIV — the period when viraemia and transmissibility are at their highest.
What should you do?
Think of it, then establish whether the exposure history supports it. Acute retroviral syndrome appears roughly 2 to 4 weeks after acquisition; fever, pharyngitis, lymphadenopathy, maculopapular rash, and mucocutaneous ulcers are the most discriminating features. But the syndrome is nonspecific, so what pushes acute HIV up the differential is a non-judgmental sexual and injection-drug history. The exposure history is often what separates “another viral illness” from “test for acute HIV today.”
Know when routine screening can miss acute HIV. The HIV Ag/Ab immunoassay detects both the p24 antigen and HIV antibodies, and the diagnostic markers become detectable in a predictable sequence after acquisition:
~Day 10: HIV RNA becomes detectable. It is not measured by the routine Ag/Ab screening assay.
~2 weeks: p24 antigen becomes detectable and may trigger the antigen component of the assay.
~3 weeks: HIV antibodies begin to appear.
Timing of HIV marker detectability after acquisition. These are population medians with considerable individual variation. Curves are qualitative and not drawn to scale. Adapted from Fiebig EW et al. 2003
Do not let a negative screen close a high-suspicion presentation. If the exposure history is compelling and acute HIV remains in the differential, a non-reactive Ag/Ab test may simply be too early. Send HIV RNA (NAT) at the same visit and ensure there is a defined pathway for result follow-up, or arrange repeat testing when appropriate.
Why it matters. Acute HIV is a hyperviraemic state, with viral loads that may reach millions of copies/mL and high potential for onward transmission. Early diagnosis allows prompt treatment, rapid viral suppression and preservation of immune function.
POC pearl: A point-of-care HIV test should not reassure you when acute HIV is strongly suspected. Many rapid tests are antibody-only, and even rapid fourth-generation assays are less reliable during very early infection. Send a laboratory Ag/Ab assay and consider HIV RNA rather than relying on POC testing alone
Snapshot 2 — Chronic HIV / clinical latency
The well patient, two years later. Same patient, feeling fine, in for an ankle sprain. Clinical latency is often asymptomatic, frequently years long, and invisible unless someone tests.
This is the opportunity cost of the missed first visit. Every ED contact during clinical latency is another screening opportunity.
Routine screening should not depend on perceived risk. US guidance recommends that adolescents and adults undergo HIV screening at least once, independent of recognised risk factors. An ED visit is therefore an opportunity to offer screening to an eligible patient who has not previously been tested.
Use an opt-out approach where supported by local policy. Present HIV screening as part of routine care and inform patients that testing will be performed unless they decline. Normalising testing improves uptake and reduces the stigma created by selectively identifying patients as “high risk.”
A reactive screen is the beginning of the diagnostic algorithm, not the diagnosis.
The next step depends on the HIV-1/HIV-2 differentiation assay, with HIV RNA resolving a negative or indeterminate differentiation result.
Interpreting the HIV screening result. Adapted from the CDC/APHL recommended laboratory HIV testing algorithm for serum or plasma specimens (2018 quick reference guide).
HIV-2 is uncommon outside epidemiologically linked populations, but is the reason the confirmatory assay differentiates HIV-1 from HIV-2.
Snapshot 3 — Advanced HIV disease
Same patient, now presenting with several weeks of progressive exertional dyspnoea, dry cough and fever. Pulse oximetry demonstrates hypoxaemia with further desaturation on exertion. The CXR shows subtle bilateral perihilar interstitial opacities, relatively unimpressive imaging for the degree of physiological disturbance.
In a patient at risk for advanced HIV, that discordance should immediately raise concern for Pneumocystis jirovecii pneumonia (PJP).
An AIDS-defining opportunistic infection establishes advanced disease regardless of the CD4 count. In a patient with confirmed HIV, the opportunistic infection in front of you is itself the staging event.
The discordance is the clue. Marked hypoxaemia with relatively modest chest-radiograph abnormalities should raise concern for PJP in the appropriate clinical context. Let the physiology, not the apparent severity of the radiograph, drive disposition.
PJP may not be the only problem. A patient this advanced warrants a broader opportunistic infection workup. Confirm HIV if not already established and early involve the admitting or ID team early. This presentation warrants admission.
The through-line: This is the visit everyone remembers, and the one the first two snapshots were trying to prevent. Every earlier ED encounter was an opportunity to diagnose HIV before advanced disease developed.
CONCLUSION
The three stages of HIV can appear in the ED as three very different presentations in the same person: acute retroviral syndrome, clinically silent chronic infection and advanced disease. The earlier the diagnosis, the greater the opportunity to preserve immune function, suppress viraemia and prevent onward transmission.
Routine opt-out Ag/Ab screening identifies otherwise silent chronic infection. Maintaining a low threshold for HIV RNA when acute infection is suspected helps close the diagnostic window before routine screening becomes reliably positive.
The aim is simple. Make the diagnosis at Snapshot 1 or 2, so Snapshot 3 never happens.
This article accompanies the HIV in Primary Care course by Dakota Price, MD. For a fuller approach to screening, diagnosis and staging, see the Screening and diagnosis chapter, including the lessons Understanding the results and Reviewing the stages of HIV.
References
HIV specific clinical cases
Price D. The Mono That Wasn’t. LITFL
Price D. Spit, Scratch, Splash, Stick. LITFL
Price D. Stage before the number. LITFL
Guidelines and algorithms
Centers for Disease Control and Prevention, Association of Public Health Laboratories. 2018 Quick Reference Guide: Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens. Published January 27, 2018.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4.
US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Jun 18;321(23):2326-2336.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV clinicalinfo.hiv.gov (accessed 2026).
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV clinicalinfo.hiv.gov (accessed 2026).
Key papers and surveillance
Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med. 1996 Apr 1;124(7):654-63.
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003 Sep 5;17(13):1871-9.
Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med. 2011 May 19;364(20):1943-54.
Dailey AF, Hoots BE, Hall HI, Song R, Hayes D, Fulton P Jr, Prejean J, Hernandez AL, Koenig LJ, Valleroy LA. Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays – United States. MMWR Morb Mortal Wkly Rep. 2017 Dec 1;66(47):1300-1306.
Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital Signs: HIV Transmission Along the Continuum of Care – United States, 2016. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):267-272.
Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2018–2022. HIV Surveillance Supplemental Report. 2024;29(No. 1).
Tan WS, Chow EP, Fairley CK, Chen MY, Bradshaw CS, Read TR. Sensitivity of HIV rapid tests compared with fourth-generation enzyme immunoassays or HIV RNA tests. AIDS. 2016 Jul 31;30(12):1951-60.
CLINICAL CASES
Microbial Mystery
More Clinical Cases
参考来源
- Life in the Fast Lane • LITFL:The Mono That Wasn't
- 全文:LITFL(CC BY-NC-SA 4.0,署名:Dakota Price)https://litfl.com/the-mono-that-wasnt/
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。